A randomized, multicentre, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Park, John (Associate Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Effective start/end date30/09/2030/09/25